Certain Toxic Effects Higher With Newer Prostate Cancer Therapies
Second-generation anti-androgens (AAs) for the treatment of prostate cancer are associated with an increased risk of cognitive and functional toxic effects, according to results from a systematic review and meta-analysis. Across 12 randomized trials involving over 13,000 patients, increased risks of cognitive toxic effects (risk ratio [RR] 2.10, 95% CI 1.30-3.38, P=0.002) and fatigue (RR […]
Zanubrutinib Tops Ibrutinib in Relapsed or Refractory CLL
Treatment with the second-generation Bruton tyrosine kinase (BTK) inhibitor led to better oncologic outcomes compared with ibrutinib (Imbruvica) for patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), according to an interim analysis of the phase III ALPINE study. Over a median follow-up of 15 months, the overall response rate — the primary […]
Second-Gen Drug for HCM Emerges, Nipping at Mavacamten’s Heels
A second-generation cardiac myosin inhibitor showed promise for the treatment of obstructive hypertrophic cardiomyopathy (HCM) in the phase II REDWOOD-HCM trial. In the dose-finding study, 10 weeks of treatment with aficamten brought resting left ventricular outflow tract (LVOT) gradients down significantly compared with placebo before a 2-week washout period returned gradients to baseline, reported Martin […]